
The National Institute for health and Care Excellence (NICE) has rejected Novartis’ CAR-T therapy Kymriah for use in adults with …

Novartis’ Kymriah is set to become the first CAR T therapy to become available on the NHS after it was …

Swiss multinational Novartis is set to create up to 450 new jobs following the investment of 90 million Swiss Francs …

Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah …

The oncology field moves so quickly that it can be hard to keep track of the latest innovations. Ben Hargreaves …

Biotech companies showing faith in their own prospect drug candidates is not an unusual occurrence, some do it to extremes. …

It’s Friday, so it’s time to bring you another run-down of the top ten most popular articles with Pharmafile.com’s readers …

Following up last year’s ground-breaking news that CAR T therapy Kymriah had become the first such treatment to be approved …

The CAR-T space has progressed rapidly over the last few years, culminating in FDA approvals for Novartis and Gilead to …

Matt Fellows investigates how the first-ever CAR-T therapy approvals in the past months could mean the field of cancer treatment …

Gilead has announced that it has completed its acquisition of Kite Pharma after the deal was announced on 28 August …

French clinical-stage biopharma firm Cellectis has received an order from the FDA to halt its study of CAR T therapy …

Takeda is set to partner with Noile-Immune Biotech in the development of a “next generation” chimeric antigen receptor T-cell (CAR …

Researchers at a General Hospital in Massachusetts has reported what they claim is the first response of a nervous system …

Researchers celebrated a world-first at the American Society of Clinical Oncology conference, revealing data which showed that, in a study …